CHEST Annual Meeting
CHEST Annual Meeting
November 17, 2015
5 min watch
Save

VIDEO: Esbriet reduces mortality in patients with IPF

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

MONTREAL — Pirfenidone appeared to reduce mortality associated with idiopathic pulmonary fibrosis, as well as all-cause mortality, compared with placebo, according to Steven D. Nathan, MD, FCCP.

Nathan discusses the results of two studies that evaluated mortality after 52, 72, and 120 weeks of Pirfenidone (Esbriet, Genentech), at CHEST Annual Meeting 2015.